Literature DB >> 8131449

Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis.

A N Hurewitz1, C L Wu, P Mancuso, S Zucker.   

Abstract

We hypothesized that inhibition of matrix-degrading metalloproteinases (MMPs) accounts for a portion of the pleural fibrosis and adhesions of tetracycline pleurodesis. MMPs recently have been described in pleural fluid from patients with both exudative and transudative effusions. Since tetracyclines are recognized inhibitors of other metalloproteinases, we investigated their inhibitory capacity in pleural fluid. High concentrations of several different tetracyclines reduced MMP activity of pleural fluid by more than 75 percent. Lower concentrations (< or = 1 mg/ml) had only modest inhibitory effects. High concentration of of tetracyclines also inhibited cell synthesis of MMPs, in vitro, but other measures of vital cell function were also impaired. We conclude that tetracyclines are effective inhibitors of MMP activity in pleural fluid and may also reduce synthesis of MMPs via non specific cell injury. These data suggest a possible mechanism to account for tetracycline pleurodesis; ie, an inhibition of MMP activity in pleural fluid.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8131449     DOI: 10.1378/chest.103.4.1113

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.

Authors:  Damian N Meli; Roney S Coimbra; Dominik G Erhart; Gerard Loquet; Caroline L Bellac; Martin G Täuber; Ulf Neumann; Stephen L Leib
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 2.  Matrix metalloproteases and lung disease.

Authors:  C M O'Connor; M X FitzGerald
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

3.  Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.

Authors:  S Wojtowicz-Praga; J Low; J Marshall; E Ness; R Dickson; J Barter; M Sale; P McCann; J Moore; A Cole; M J Hawkins
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

5.  Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(®) Injection) for Malignant Pleural Effusion.

Authors:  Jeong Su Cho; Kook Joo Na; Yongjik Lee; Yeong Dae Kim; Hyo Yeong Ahn; Chang Ryul Park; Young Chul Kim
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-12-04       Impact factor: 1.520

Review 6.  Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration.

Authors:  Michal Mierzejewski; Piotr Korczynski; Rafal Krenke; Julius P Janssen
Journal:  Respir Res       Date:  2019-11-07

7.  Drug Eluting Embolization Particles for Permanent Contraception.

Authors:  Hannah VanBenschoten; Shan Yao; Jeffrey T Jensen; Kim A Woodrow
Journal:  ACS Biomater Sci Eng       Date:  2022-06-24

8.  Comparisons of doxycycline solution with talc slurry for chemical pleurodesis and risk factors for recurrence in South Korean patients with spontaneous pneumothorax.

Authors:  Eun Ha Park; Joo Hee Kim; Jeong Yee; Jee Eun Chung; Jong Mi Seong; Hyen Oh La; Hye Sun Gwak
Journal:  Eur J Hosp Pharm       Date:  2018-04-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.